CN104547078A - Clysis fluid for treating postoperative early adhesion intestinal obstruction - Google Patents
Clysis fluid for treating postoperative early adhesion intestinal obstruction Download PDFInfo
- Publication number
- CN104547078A CN104547078A CN201510006102.9A CN201510006102A CN104547078A CN 104547078 A CN104547078 A CN 104547078A CN 201510006102 A CN201510006102 A CN 201510006102A CN 104547078 A CN104547078 A CN 104547078A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- folium
- enema
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 14
- 208000003243 intestinal obstruction Diseases 0.000 title abstract description 7
- 239000012530 fluid Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 14
- 241000746375 Andrographis Species 0.000 claims abstract description 10
- 241000218176 Corydalis Species 0.000 claims abstract description 9
- 241000628997 Flos Species 0.000 claims description 22
- 241000792859 Enema Species 0.000 claims description 13
- 239000000853 adhesive Substances 0.000 claims description 13
- 239000007920 enema Substances 0.000 claims description 13
- 229940095399 enema Drugs 0.000 claims description 13
- 230000001070 adhesive effect Effects 0.000 claims description 12
- 239000010231 banlangen Substances 0.000 claims description 12
- 208000008384 ileus Diseases 0.000 claims description 12
- 241001533451 Ajuga ciliata Species 0.000 claims description 11
- 239000009806 pulsatillae Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000167550 Centella Species 0.000 abstract 1
- 240000005250 Chrysanthemum indicum Species 0.000 abstract 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 abstract 1
- 241001503991 Consolida Species 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 241000206469 Pulsatilla Species 0.000 abstract 1
- 241000612118 Samolus valerandi Species 0.000 abstract 1
- 244000288377 Saxifraga stolonifera Species 0.000 abstract 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 description 14
- 239000003440 toxic substance Substances 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000003187 abdominal effect Effects 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 229930182486 flavonoid glycoside Natural products 0.000 description 7
- 150000007955 flavonoid glycosides Chemical class 0.000 description 7
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 7
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 7
- 235000009498 luteolin Nutrition 0.000 description 7
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 208000019790 abdominal distention Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000015220 Febrile disease Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 230000001088 anti-asthma Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010000050 Abdominal adhesions Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 2
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical group C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 239000008589 Cortex Fraxini Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241001264480 Lycopodiastrum casuarinoides Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010058113 Meconium peritonitis Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 235000000533 Rosa gallica Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011462 intraperitoneal chemotherapy Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003801 laryngeal nerve Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicine application and in particular discloses clysis fluid for treating postoperative early adhesion intestinal obstruction. The clysis fluid for treating postoperative early adhesion intestinal obstruction is prepared by the following steps: taking mother chrysanthemum, common andrographis herb, the root of Chinese pulsatilla, saxifraga stolonifera, centella, isatis root, herba orostachyos, folium polygoni tinctorii, carpet bugle, bunge corydalis herb, honeysuckle and folium eucalypti robustae, mixing and decocting the materials according to a certain weight ratio, thereby obtaining the product. The clysis fluid disclosed by the invention is easy to prepare, good in absorption effect, long in drug effect duration, obvious in curative effect, high in safety and low in production cost and does not have any side effect, and the disease symptoms of patients are timely alleviated.
Description
(1) technical field
The present invention relates to application in TCM field, particularly a kind of enema for the treatment of early postoperative period adhesive ileus.
(2) background technology
Adhesive ileus is the congenital factor of intraperitoneal except minority, outside caused by congenital dysplasia or meconium peritonitis, is mostly acquired.Common cause is Abdominal inflammation, damage, hemorrhage, foreign body in abdominal cavity, and after being more common in abdominal operation or Abdominal inflammation, wherein the adhesion of abdominal postoperative is the ileac the first cause of disease at present, and abdominal cavity radiotherapy and intraperitoneal chemotherapy also can cause viscosity intestinal obstruction in addition.Operation on pelvis (as gynecilogical operation, appendectomy and Colon and rectum Post operation) and lower abdominal surgery especially easily produce intestinal adhesion and intestinal obstruction, and its reason is that pelvic cavity small intestinal is more free, and epigastrium small intestinal is then relatively fixing.But the patient of intestinal adhesion intestinal obstruction might not occur, and sticking together property intestinal obstruction does not necessarily represent abdominal cavity yet extensive, serious adhesion.Only have and make being fixed fettered by intestinal loop by generation obstacle, adhesion band two ends of intestinal contents when intestinal tube sticky point forms acute angle, or one group of intestinal loop adhesion is agglomerating, intestinal wall has cicatricial stricture just can cause adhesive ileus.
At present, this disease generally betides abdominal postoperative 1-3 week, is generally not difficult to judge, but the method for the treatment of is complicated, there is no definite therapeutic scheme at present, and western medical treatment is still based on operation, and effect is also not satisfactory, and medical expense is high, the cycle is long.
(3) summary of the invention
The present invention, in order to make up the deficiencies in the prior art, provides a kind of Chinese medicinal herbs decoction preparing treatment early postoperative period adhesive ileus simple, evident in efficacy.
The present invention is achieved through the following technical solutions:
Treat an enema for early postoperative period adhesive ileus, be made up of the Chinese medicine of following parts by weight: Flos Chrysanthemi Indici 30-60 part, Herba Andrographis 30-62 part, Radix Pulsatillae 32-63 part, Herba Saxifragae 33-65 part, Herba Centellae 31-61 part, Radix Isatidis 32-62 part, Herba Orostachyos 30-62 part, Folium Polygoni Tinctorii 30-61 part, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 31-62 part, Herba Corydalis Bungeanae 32-63 part, Flos Lonicerae 31-62 part, Folium Eucalypti Robustae 30-61 part.
The weight proportion of its preferred each raw material is:
Flos Chrysanthemi Indici 30 parts, Herba Andrographis 30 parts, the Radix Pulsatillae 32 parts, Herba Saxifragae 33 parts, Herba Centellae 31 parts, Radix Isatidis 32 parts, Herba Orostachyos 30 parts, Folium Polygoni Tinctorii 30 parts, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 31 parts, Herba Corydalis Bungeanae 32 parts, Flos Lonicerae 31 parts, Folium Eucalypti Robustae 30 parts.
Chinese medicine of the present invention is enema, gets said medicine liquor at twice, decocting, filtering residue, and after cooling, sealing point is filled in 150ml packaging bag, namely makes enema of the present invention.
Wherein the pharmaceutical characteristic of each raw material is:
Flos Chrysanthemi Indici: bitter in the mouth, pungent, property is put down; Return lung, Liver Channel.Heat-clearing and toxic substances removing; Dispelling wind suppressing the hyperactive liver.Main furuncle; Carbuncle; Erysipelas; Eczema; Dermatitis; Anemopyretic cold; Laryngopharynx swelling and pain; Hypertension; Removing toxic substances, reduces internal heat and relieves summer heat, antibacterial, blood pressure lowering, and sterilization goes to swell.
Herba Andrographis: heat-clearing and toxic substances removing, removing heat from blood, detumescence.The heat and toxic materials clearing away medicine belonged in antipyretic subordinate mainly has refrigeration function; Multiple andrographolide and various injection all have antipyretic response; Also have resisting pathogenic microbes and antiinflammatory, enhancing immunologic function; The platelet aggregation that total flavones vivo and vitro can suppress ADP to induce, rat myocardium from injury caused by anti-isoproterenol and have certain protective role to experimental myocardial infarction rabbit; In addition, venom, antifertility action is also had.
The Radix Pulsatillae: toxic-heat and blood stasis, tenesmus, damp-heat vaginal discharge, pyrexial malaria cold and heat.Fresh juice, decoct have significant inhibitory action to various bacteria.Soup and four medicines thereof all have pathogenic entero becterias such as various dysentery bacteriums and suppress effect significantly, and wherein the strongest with Rhizoma Coptidis, Cortex Fraxini effect, Cortex Phellodendri takes second place, and the Radix Pulsatillae is the most weak, there is no collaborative between each medicine, also without antagonism.The antibiotic effective ingredient of this product is protoanemonin and Anemonin.Antibacterial activity and the strepto-of Anemonin have synergism.
Herba Centellae: clearing away heat-damp and promoting diuresis, subduing swelling and detoxicating.Control eruptive disease stomachache, diarrhea due to summer-heat, dysentery, jaundice due to damp-heat, sand Stranguria, stranguria with blood, tells, is defeated in battle, hemoptysis, conjunctival congestion, and larynx swells, rubella, scabies, furuncle carbuncle poison, traumatic injury.Heat-clearing and toxic substances removing, inducing diuresis and reducing edema.Be the long-lived medicine of Asians, can refresh oneself by beneficial brain.Research shows to have nourishing, antiinflammatory, healing of wound, diuresis relieving constipation and calm effect.Also effective in cure to leprosy, ulcer, there is activation to blood purification and immunity, because it can stimulate the replacement of deep skin cell.It is neural nourishing agent, can improve memory, alleviate mental fatigue; Also can blood pressure lowering, treatment hepatopathy etc.Can promote skin growth, local leukocytosis, connective tissue vasoganglion increases, and mucilage secretion increases, and fur hypertrophy is accelerated, and has the effect suppressing skin ulcer.
Radix Isatidis: bitter in the mouth, cold in nature, has the effects such as heat-clearing and toxic substances removing, removing heat from blood, speckle removing, sore-throat relieving, is mainly used in the treatment of the disease such as epidemic febrile disease heating, headache, laryngalgia, macule, mumps, carbuncle sore tumefacting virus.Radix Isatidis has external broad-spectrum antibacterial action (comprising dysentery antibacterial, salmonella bacteria, hemolytic rope-forming bacteria), be anti-inflammation, pain relieving, the Chinese traditional herbs of bringing down a fever.Containing multiple antiviral substance in Radix Isatidis, there are stronger suppression and killing action to cold virus, mumps virus, hepatitis virus and epidemic encephalitis virus etc.Radix Isatidis and Rhizoma Osmundae, Flos Lonicerae, Flos Chrysanthemi Indici etc. share, and are used for the treatment of some infectious disease and febrile disease.
Herba Orostachyos: heat-clearing and toxic substances removing hemostasis, inducing diuresis and reducing edema effect, heat-clearing and toxic substances removing, hemostasis, dampness removing, detumescence.Control haematemesis, epistaxis, dysentery, hepatitis, malaria, pyretic stranguria, hemorrhoid, eczema, carbuncle poison, furuncle, soup fire is burnt.Folium Polygoni Tinctorii: heat-clearing and toxic substances removing, blood cooling and ecchymoses removing, generates heat for epidemic febrile disease; Send out speckle dermexanthesis; Hematemesis and epistaxis; Sore throat; Hematodiarrhoea; Jaundice; Erysipelas; Mumps; Aphtha; Carbuncle.
Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.): alcohol-ether extract has inhibitory action to alpha streptococcus, staphylococcus aureus, streptococcus pneumoniae, escherichia coli and bacillus pyocyaneus; Flavonoid glycoside (10mg/ml) all has inhibitory action to staphylococcus glucose coccus, alpha streptococcus, micrococcus catarrhalis and streptococcus pneumoniae; 10% Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) preserved material, 10% coated tablet and flavone all have the effect suppressing 68-1 influenza virus in obvious Embryo Gallus domesticus.Luteolin 10mg/ml has inhibitory action to staphylococcus aureus, α-hemolytic streptococcus, micrococcus catarrhalis, streptococcus pneumoniae, bacillus pyocyaneus, 700mg/kg gavage, has anti-infectious function, obviously reduce mortality rate to the mice infecting staphylococcus aureus.The mouse ear inflammation that xylol causes has obvious inhibitory action, and its ED50 is 106mg/kg.Luteolin 80,160mg/kg intramuscular injection, on Carrageenan, the rat ankle joint that yeast brings out is swollen, and swollen and Oleum Tiglii brings out has rat granuloma all to have obvious inhibitory action, but 30,60mg/kg intramuscular injection, continuous 30 days, can increase the sickness rate of the experimental allergic encephalomyelitis of Cavia porcellus, prompting has immunological enhancement.Luteolin 80,120,160mg/kg intramuscular injection, the rat pleural that Dichlorodiphenyl Acetate brings out is scorching, and its transudate can be made to reduce, and to total white blood cells in transudate without obvious change.Luteolin 180mg/kg gavage, generates normal mouse hemolytic antibody and special red rose pigment rate has no significant effect, but improves the immunologic function of cyclophosphamide suppression rabbit epidemic disease mice, and these two indexs are all improved.When luteolin final concentration is 1.09 × 10-4mol/L, can suppress sensitized guinea pig isolated ileal rings anaphylaxis contractile response, shrink the guinea pig ileum that SRS-A causes, also have inhibitory action, its IC50 is 2.76 × 10-5mol/L.Luteolin 4 × 10-4 concentration also has inhibitory action to egg protein sensitized guinea pig lung rat tissue release histamine and SRS-A.Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) acid alcohol extract 112, flavonoid glycoside, total acid phenol, total alkaloids, crystallization (I) and Saponin, all there is certain antitussive action, wherein the antitussive action similar intensity of flavonoid glycoside (2.5mg/ only) and codeine (0.4mg/ only); It act as and directly suppresses coughing centre.Prove that acid alcohol extract 112, flavonoid glycoside, total acid phenol, alkaloid and crystallization (I) all have certain phlegm-dispelling functions by the phenol red method of mice; It act as directly stimulates respiratory mucosa secretory cell, secretion is increased, to expectorant inner acidic mucopolysaccharide fiber, also there is certain dissolution, and have the effect reducing capillary permeability, the permeability of trachea when illustrating that its flavonoid glycoside can reduce inflammation, thus play antiinflammatory phlegm-dispelling functions.Acid alcohol extract, flavonoid glycoside and alkaloid have antiasthmatic effect in various degree to experimental animal models asthma, and wherein the flavonoid glycoside of 250mg/kg equals the antiasthmatic effect of 125mg/kg aminophylline; Antiasthmatic effect is due to direct expansion bronchus smooth muscle and has caused by stronger anti-infectious function.Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) effective ingredient luteolin 250mg/kg gavage, 25mg/kg lumbar injection, draw ammonia mist and cough mice and all have antitussive effect, 30mg/kg intravenous injection, stimulates superior laryngeal nerve to draw to cough and also have inhibitory action to anesthetized cat; 100mg/kg gavage, shows there is phlegm-dispelling functions to mice PSP method, 100mg/kg intravenous injection, and the bronchial smooth muscle that can cause antihistamine shrinks.
Herba Corydalis Bungeanae: heat-clearing and toxic substances removing, anti-inflammation, reducing swelling and alleviating pain, antiviral.
Flos Lonicerae: one is antibacterial and antiviral.Namely obvious inhibitory action is had to staphylococcus aureus, Hemolytic streptococcus, dysentery, typhoid fever, meningococcus, Diplococcus pneumoniae, green pus and influenza virus etc.; Two is have the function strengthening immunity.Flos Lonicerae can promote lymphocyte transformation, strengthens leukocytic phagocytic function; Three is antiinflammatories, antipyretic.Flos Lonicerae can promote the release of adrenocortical hormone, has obvious inhibitory action to inflammation.
Folium Eucalypti Robustae: heat-clearing and toxic substances removing, convergence granulation promoting, dispelling wind for relieving itching, clear heat radiation thoroughly.
In formula, Folium Eucalypti Robustae, Folium Polygoni Tinctorii, Herba Orostachyos have heat-clearing and toxic substances removing, convergence granulation promoting, inducing diuresis and reducing edema effect; Lycopodium casuarinoides Spring, Flos Lonicerae, Radix Isatidis have the effect of bactericidal antiphlogistic, have obvious dissipation effect to the antibacterial that enteral produces; Be equipped with Flos Chrysanthemi Indici, the Radix Pulsatillae, Herba Andrographis sterilization detumescence again, removing the necrotic tissue and promoting granulation, easing pain and diminishing inflammation, enhancing immunity, making originally can effective treatment adhesive ileus.
The present invention is with bactericidal antiphlogistic, and removing the necrotic tissue and promoting granulation, reducing swelling and alleviating pain is the rule for the treatment of, and multiple medical material combination is collaborative, is mainly used in heat-clearing and toxic substances removing, and convergence granulation promoting, dispelling wind for relieving itching, disappear heat radiation, has significant therapeutic effect to the enema of early postoperative period adhesive ileus.
Clinical observation:
(1) clinical data
The present inventor in calendar year 2001 so far, clinical observation treatment is carried out to 274 routine early postoperative period adhesive ileus patients, wherein, male 205 example, women 69 example.
(2) Therapeutic Method
Every day potion, after supper defecation coloclysis be detained treatment, within three days, be a course for the treatment of, according to conditions of patients weight calculate treatment time, cure after 2-3 the course for the treatment of after patients with mild coloclysis, severe case 5-6 cured after the course for the treatment of.
(3) curative effect determinate standard
Criterion of therapeutical effect is with reference to criterion of therapeutical effect relevant in " disease of tcm judgement criterion of therapeutical effect ".
Cure: patient suffers from abdominal pain, abdominal distention disappears, and defecation is normal, after feed semiliquid diet without Nausea and vomiting abdominal part without tenderness, abdominal radiograph Non Apparent Abnormality.
Effective: clinical symptom relief abdominal distention stomachache attack times obviously reduces.
Effective: clinical symptom relief abdominal distention stomachache attack times reduces.
Invalid: patient's abdominal distention stomachache increases the weight of, and even has muscle tonus, the prompting of abdominal radiograph, abdominal CT blocks sign without alleviating or increasing the weight of, and occurs peritonitis, guttie situation person.
(4) clinical effectiveness
Clinical cure 215 example (78.47%), effective 39 examples (14.23%), effective 17 examples (6.21%), invalid 3 examples (1.09%), total effective rate is 98.91%.
The present invention prepares simply, good absorbing effect, and duration of efficacy is long, evident in efficacy, has no side effect, and safety is high, and production cost is low, is conducive to sufferer and alleviates condition of illness in time.
(4) detailed description of the invention
Embodiment 1:
Get Flos Chrysanthemi Indici 30 parts, Herba Andrographis 30 parts, the Radix Pulsatillae 32 parts, Herba Saxifragae 33 parts, Herba Centellae 31 parts, Radix Isatidis 32 parts, Herba Orostachyos 30 parts, Folium Polygoni Tinctorii 30 parts, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 31 parts, Herba Corydalis Bungeanae 32 parts, Flos Lonicerae 31 parts, Folium Eucalypti Robustae 30 parts, get said medicine liquor at twice, decocting, filtering residue, after cooling, sealing point is filled in 150ml packaging bag, namely makes enema of the present invention.
Usage and dosage: every day potion, after supper defecation coloclysis be detained treatment, within three days, be a course for the treatment of.
Embodiment 2:
Get Flos Chrysanthemi Indici 60 parts, Herba Andrographis 62 parts, the Radix Pulsatillae 63 parts, Herba Saxifragae 65 parts, Herba Centellae 61 parts, Radix Isatidis 62 parts, Herba Orostachyos 62 parts, Folium Polygoni Tinctorii 61 parts, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 62 parts, Herba Corydalis Bungeanae 63 parts, Flos Lonicerae 62 parts, Folium Eucalypti Robustae 61 parts, get said medicine liquor at twice, decocting, filtering residue, after cooling, sealing point is filled in 150ml packaging bag, namely makes enema of the present invention.
Usage and dosage: every day potion, after supper defecation coloclysis be detained treatment, within three days, be a course for the treatment of.
Embodiment 3:
Get Flos Chrysanthemi Indici 50 parts, Herba Andrographis 51 parts, the Radix Pulsatillae 52 parts, Herba Saxifragae 51 parts, Herba Centellae 51 parts, Radix Isatidis 52 parts, Herba Orostachyos 53 parts, Folium Polygoni Tinctorii 50 parts, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 51 parts, Herba Corydalis Bungeanae 51 parts, Flos Lonicerae 50 parts, Folium Eucalypti Robustae 53 parts, get said medicine liquor at twice, decocting, filtering residue, after cooling, sealing point is filled in 150ml packaging bag, namely makes enema of the present invention.
Usage and dosage: every day potion, after supper defecation coloclysis be detained treatment, within three days, be a course for the treatment of.
Claims (3)
1. treat an enema for early postoperative period adhesive ileus, it is characterized by, be made up of the Chinese medicine of following parts by weight: Flos Chrysanthemi Indici 30-60 part, Herba Andrographis 30-62 part, Radix Pulsatillae 32-63 part, Herba Saxifragae 33-65 part, Herba Centellae 31-61 part, Radix Isatidis 32-62 part, Herba Orostachyos 30-62 part, Folium Polygoni Tinctorii 30-61 part, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 31-62 part, Herba Corydalis Bungeanae 32-63 part, Flos Lonicerae 31-62 part, Folium Eucalypti Robustae 30-61 part.
2. a kind of enema for the treatment of early postoperative period adhesive ileus according to claim 1, is characterized by, be made up of the Chinese medicine of following parts by weight: Flos Chrysanthemi Indici 30 parts, Herba Andrographis 30 parts, the Radix Pulsatillae 32 parts, Herba Saxifragae 33 parts, Herba Centellae 31 parts, Radix Isatidis 32 parts, Herba Orostachyos 30 parts, Folium Polygoni Tinctorii 30 parts, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 31 parts, Herba Corydalis Bungeanae 32 parts, Flos Lonicerae 31 parts, Folium Eucalypti Robustae 30 parts.
3. a kind of enema for the treatment of early postoperative period adhesive ileus according to claim 1 and 2, is characterized in that: get said medicine liquor at twice, decocting, filtering residue, and after cooling, sealing point is filled in 150ml packaging bag, namely makes enema of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510006102.9A CN104547078A (en) | 2015-01-07 | 2015-01-07 | Clysis fluid for treating postoperative early adhesion intestinal obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510006102.9A CN104547078A (en) | 2015-01-07 | 2015-01-07 | Clysis fluid for treating postoperative early adhesion intestinal obstruction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104547078A true CN104547078A (en) | 2015-04-29 |
Family
ID=53064849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510006102.9A Pending CN104547078A (en) | 2015-01-07 | 2015-01-07 | Clysis fluid for treating postoperative early adhesion intestinal obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547078A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922251A (en) * | 2015-07-10 | 2015-09-23 | 刘杰 | Clysis liquid treating adhesive ileus |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933177A (en) * | 2014-05-09 | 2014-07-23 | 张艳梅 | Preparation method of medicament for treating intestinal obstruction |
| CN103977109A (en) * | 2014-04-12 | 2014-08-13 | 邵阳市中医医院 | Drug for treating paralytic ileus and promoting stomach and intestine function recovery after abdominal operation and preparation method thereof |
| CN104189772A (en) * | 2014-09-19 | 2014-12-10 | 宋秀花 | Traditional Chinese medicine for treating adhesive intestinal obstruction |
| CN104324328A (en) * | 2014-11-20 | 2015-02-04 | 赵静 | Traditional Chinese medicine composition for ileus and preparation method of traditional Chinese medicine composition |
-
2015
- 2015-01-07 CN CN201510006102.9A patent/CN104547078A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977109A (en) * | 2014-04-12 | 2014-08-13 | 邵阳市中医医院 | Drug for treating paralytic ileus and promoting stomach and intestine function recovery after abdominal operation and preparation method thereof |
| CN103933177A (en) * | 2014-05-09 | 2014-07-23 | 张艳梅 | Preparation method of medicament for treating intestinal obstruction |
| CN104189772A (en) * | 2014-09-19 | 2014-12-10 | 宋秀花 | Traditional Chinese medicine for treating adhesive intestinal obstruction |
| CN104324328A (en) * | 2014-11-20 | 2015-02-04 | 赵静 | Traditional Chinese medicine composition for ileus and preparation method of traditional Chinese medicine composition |
Non-Patent Citations (1)
| Title |
|---|
| 叶礼燕: "《儿科辨病专访治疗》", 30 June 2000, 人民卫生出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922251A (en) * | 2015-07-10 | 2015-09-23 | 刘杰 | Clysis liquid treating adhesive ileus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101983708B (en) | Traditional Chinese medicine for clearing lung and eliminating phlegm | |
| CN102920955B (en) | External traditional Chinese medicine composition for treating dermatophytosis, preparation method and application | |
| CN103933128A (en) | Pharmaceutical composition for clearing away heat and toxic materials and preparation method thereof | |
| CN104435890A (en) | Traditional Chinese medicine composition for treating hepatic calculus | |
| CN104116830A (en) | Medicinal liquor for treating pulmonary abscess and preparation method thereof | |
| CN103494927A (en) | Traditional Chinese medicine composition for treating chicken respiratory disease and preparation method thereof | |
| CN103142733B (en) | Chinese medicine composition for treating upper respiratory infection | |
| CN103610915B (en) | Traditional Chinese medicine for treating swelling and pain in throat | |
| CN104940729A (en) | Traditional Chinese medicine for treating cholelithiasis | |
| CN104547078A (en) | Clysis fluid for treating postoperative early adhesion intestinal obstruction | |
| CN107596271A (en) | A kind of clear pest anti virus herb composition | |
| CN103405722B (en) | Chinese herba preparation for preventing and treating infantile cough | |
| CN106266376A (en) | A kind of Chinese medicine composition for treating staphylococcus aureus | |
| CN104258020A (en) | Traditional Chinese medicine composition for treating pneumonia | |
| CN105147912A (en) | Traditional Chinese medicine composition for cough and asthma of poultry | |
| CN104922251A (en) | Clysis liquid treating adhesive ileus | |
| CN103585580A (en) | Chinese medicinal preparation for treating recurrent oral ulceration | |
| CN104587034B (en) | New application of a medicinal composition in treating oral ulcer | |
| CN104606350A (en) | Medicament for treating throat-blocking abscess | |
| CN103623261B (en) | A kind of Chinese powder medicine for the treatment of oral ulcer and preparation method thereof | |
| CN102397448A (en) | Chinese herbal medicine for treating toothache | |
| CN102614362B (en) | Preparation method for traditional Chinese medicine lotion for treating smoking type ecthyma | |
| CN103463401B (en) | Asthma medicine for infants | |
| CN105343485A (en) | Medicine composition for treating nasosinusitis and application thereof | |
| CN106074900A (en) | A kind of Chinese medicine composition of adjuvant treatment of acute pulmonary abscess |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150429 |